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Previously genome-wide association methods in patients with classic bladder exstrophy (CBE) found 
association with ISL1, a master control gene expressed in pericloacal mesenchyme. This study sought 
to further explore the genetics in a larger set of patients following-up on the most promising genomic 
regions previously reported. Genotypes of 12 markers obtained from 268 CBE patients of Australian, 
British, German Italian, Spanish and Swedish origin and 1,354 ethnically matched controls and from 
92 CBE case-parent trios from North America were analysed. Only marker rs6874700 at the ISL1 locus 
showed association (p = 2.22 × 10−08). A meta-analysis of rs6874700 of our previous and present study 
showed a p value of 9.2 × 10−19. Developmental biology models were used to clarify the location of 
ISL1 activity in the forming urinary tract. Genetic lineage analysis of Isl1-expressing cells by the lineage 
tracer mouse model showed Isl1-expressing cells in the urinary tract of mouse embryos at E10.5 and 
distributed in the bladder at E15.5. Expression of isl1 in zebrafish larvae staged 48 hpf was detected in 
a small region of the developing pronephros. Our study supports ISL1 as a major susceptibility gene for 
CBE and as a regulator of urinary tract development.
The bladder exstrophy-epispadias complex (BEEC; OMIM %600057) represents the severe end of human congen-
ital anomalies of the kidney and urinary tract (CAKUT), and involves the abdominal wall, pelvis, all of the uri-
nary tract, the genitalia, and occasionally the spine and anus. Birth prevalence rates for the most common defect 
form, classic bladder exstrophy (CBE), range from 1 in 30,000 to 1 in 50,000, varying among North American 
ethnic groups with the highest prevalence being observed among Native Americans (8 in 100,000) and the lowest 
among Asians (1 in 100,000)1,2. Vesicoureteral reflux and obstruction of the ureteropelvic junction are observed 
frequently in both genders, and cryptorchidism is common in males3. Long-term complications are malignancies 
of the bladder mucosa, with 95% of these malignancies being adenocarcinomas4.
To identify susceptibility loci for CBE, we recently performed a genome-wide association study (GWAS) of 
110 CBE patients and 1,177 controls of European origin. Here, an association was found with a region of approxi-
mately 220 kb on chromosome 5q11.1-q11.25. This region harbors the ISL1 (ISL LIM homeobox 1) gene. Multiple 
markers in this region showed evidence for association with CBE, including 84 markers with genome-wide sig-
nificance. A subsequent meta-analysis using data from a previous GWAS by our group of 98 CBE patients and 
526 controls of European origin also implicated the 5q11.1-q11.2 locus in CBE risk5,6. A total of 138 markers at 
this locus reached genome-wide significance in the meta-analysis. No other locus in the meta-analysis achieved 
genome-wide significance.
The present association study followed-up on the most promising genomic regions based on the results of our 
previous meta-analysis defined by a total of 12 independent markers. One of these markers resides in the ISL1 
region and had previously reached genome-wide significance5. The other 11 markers had previously reached 
p values of 10−05 5. The study sample before quality control (QC) steps of the generated genotypes comprised 274 
Australian, British, German, Italian, Spanish, and Swedish CBE patients and 1,365 ethnically matched controls, 
and 110 case-parent trios from North America of European background. To better understand the role of ISL1 
during genito-urinary tract development, we performed expression studies in mouse embryos and zebrafish lar-
vae (zfl).
Results
Association study. After performance of QC steps for the generated genotypes we had to exclude six CBE 
patients and 11 of the ethnically matched controls from the case-control study. Hence the analyzed data set for the 
case-control study comprised 268 CBE patients of Australian (n = 31), British (n = 40), German (n = 7), Italian 
(n = 39), Spanish (n = 35), and Swedish (n = 116) origin and 1,354 ethnically matched controls. In controls, 
there was no evidence for deviation from Hardy-Weinberg equilibrium for any of the 12 SNPs (data not shown). 
Accordingly we had to exclude 18 of the CBE case-parent trios from North America of European from the trans-
mission disequilibrium test (TDT). Hence the analyzed data set for the TDT comprised 92 case-parent trios from 
North America of European background. Table 1 shows the results of the association analyses for the 268 cases, 
the ethnically matched 1,354 controls, the 92 case-parent trios, and the combined meta-analysis. A more detailed 
description of the results of the TDT is shown in the Supplementary (Supplementary Table 1). A significant result 
was observed for the marker rs6874700 at chromosome 5q11.2, representing the ISL1 locus (p = 2.22 × 10−08). A 
meta-analysis for the marker rs6874700 of our previous and present study showed a p value of 9.2 × 10−19. The 
relative risk (RR) (95% CI) for rs6874700 in this meta-analysis was 1.93 (95% CI, 1.67–2.23) (Table 2).
Lineage analysis of Isl1-expressing cells in mouse embryos. Lineage tracing provides a pow-
erful means of understanding tissue development, homeostasis, and disease, especially when it is combined 
with experimental manipulation of signals regulating cell fate decisions. In order to address the contribution 
of Isl1-expressing cells in the developing early genito-urinary tract, we used the Isl1-mER-Cre-mER allele in 
which sequences encoding a tamoxifen dependent Cre recombinase were inserted into the Isl1 locus7. Here 
Isl1-expressing cells were observed in the early genito-urinary tract of mouse embryo at E10.5 (Fig. 1A, arrow). 
Isl1-expressing cells later distributed in the bladder at E15.5 (Fig. 1B). To further analyze the involvement of 
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Isl1- expressing cells for the bladder formation, we performed detailed cell lineage analysis by conducting sev-
eral timing of tamoxifen treatments. An increasing number of Isl1-expressing cells at E7.5 were detected in the 
early genito-urinary tract and bladder region (Fig. 1C,F). Of note, a large number of Isl1-expressing cells were 
observed in such regions after the treatment of tamoxifen at E8.5 and E9.5 (Fig. 1D,E,G,H). In addition to the 
bladder, Isl1-expressing cells also contributed to the genital tubercle region (Fig. 1F–H, arrowheads). To further 
investigate the contribution of Isl1-expressing cells for caudal body formation, we analyzed the Hoxa3-IRESCre; 
Isl1Flox/Flox mutant embryos (Isl1 cKO). Hoxa3 Cre driver mouse line possesses Cre activity in the caudal body 
regions8. Isl1 cKO showed the hypoplasia of GT (Fig. 1I–L, red arrows) as well as bladder (Fig. 1K,L, circle). The 
embryonic time dependent Isl1 positive mesenchymal cell population was thus discussed further in Discussion.
Whole mount in situ hybridization (WISH) of zebrafish larvae (zfl). In contrast to mammals, in 
early developmental stages of zfl between 48–96 hours post fertilisation (hpf) the pronephros containing two 
glomeruli plus nephrons, is already fully functional. In adult fish the subsequently developing mesonephros will 
yet become the final kidneys. In mammals however only the hereafter developing metanephros will become the 
final kidney9. In the early developing zfl, just after gastrulation (tail-bud stage around 10 hpf) first renal progen-
itors can be detected in bilateral stripes of intermediate mesoderm (IM), located either side of the embryonic 
midline in between the paraxial mesoderm (PM) and the lateral plate mesoderm (LPM)10. These renal progenitor 
fields give then, from about 10 somite stage, rise to a pair of bilateral nephrons. The pronephros itself is again 
comprised of a series of discrete cell types, well differentiable approximately from the prim-5 stage on at around 
26 hpf11,12. To test for a potential involvement of isl1 in the above described renal progenitor development in zfl, 
our first step was to investigate isl1 expression at these sides during the respective time points by whole mount 
RNA in situ hybridization (WISH) expression analysis in the early wt zfl between 22 and 60 hpf (corresponding 
approximately to 26 somite and pec-fin stage). Using an antisense in situ probe comprising an UTR region of zfl 
isl1 cDNA (see methods section13,14) we could clearly detect isl1 expression in some region of the developing pro-
nephros for all tested time points mentioned above. At 48 hpf we could clearly detect isl1 expression at most ante-
rior regions of the proximal convoluted tubular (PCT) regions (Fig. 2), which we co-localized with a previously 
described slc20a1a in situ marker12. Long-peg stage zfl at 48 hpf showed isl1 expression in regions close to the 
yolk-sac, which have previously been described as the early developing pancreatic region15, but do also overlap 
with slc20a1a marker expression here in the most anterior developing nephros region (Fig. 2).
Discussion
Following-up on the most promising genomic regions based on the results of our previous meta-analysis in a 
total of 360 CBE patients, we were able to replicate our findings on the ISL1 harboring region with the marker 
rs6874700 (p = 2.22 × 10−8). A meta-analysis for the marker rs6874700 of our previous and present study showed 
a p value of 9.2 × 10−19. The relative risk (RR) (95% CI) for rs6874700 in this meta-analysis was 1.93 (95% CI, 
1.67–2.23).
SNP
Chromosome/
Region Position
Risk/
other 
allele
Meta-analysis Cases 
(n = 268) vs. controls 
(n = 1,354) (AUS/GB/DE/
IT/ES/SE) RR (95% CI)
TDT Case-parent 
trios (n = 92) 
(North America) 
RR (95% CI)
Meta-analysis Cases (n = 268), 
Controls (n = 1,354), Case-
parent trios (n = 92) RR (95% 
CI) p values
rs1475601 1q31.3 194,721,655 G/A 1.11 (0.60–2.05) 0.88 (0.32–2.41) 1.04 (0.61–1.76) 0.884
rs72748303 1q32.2 208,973,633 A/G 1.54 (0.95–2.52) 0.71 (0.23–2.25) 1.37 (0.87–2.15) 0.170
rs79145914 4p14 39,490,706 G/A 1.26 ( 0.74–2.14) 1.75 (0.51–5.98) 1.33 (0.82–2.15) 0.254
rs7689350 4q13.3 76,207,570 A/C 0.98 (0.70–1.38) 2.13 (0.92–4.92) 1.10 (0.80–1.51) 0.568
rs6874700 5q11.2 50,701,750 A/T 1.80 (1.44–2.25) 1.61 (1.07–2.41) 1.75 (1.44–2.13) 2.2 × 10−08
rs1514351 6q12 68,694,074 C/T 1.20 (0.96–1.50) 0.91 (0.60–1.39) 1.13 (0.92–1.37) 0.239
rs117622209 6q22.1 118,108,159 C/T 1.12 (0.64–1.96) 1.20 (0.37–3.93) 1.13 (0.69–1.88) 0.623
rs56189125 7p14.3 28,855,348 G/A 1.05 (0.09–11.78) 1.67 (0.61–4.59) 1.56 (0.61–3.96) 0.353
rs57086087 8p11.21 40,301,811 T/C 1.07 (0.80–1.44) 1.42 (0.84–2.39) 1.15 (0.89–1.48) 0.301
rs10119066 9p24.1 7,509,895 T/G 0.99 (0.66–1.50) 1.60 (0.52–4.89) 1.05 (0.71–1.55) 0.806
rs16917077 9p21.1 31,532,212 C/T 1.39 (0.74–2.59) 1.38 (0.55–3.42) 1.38 (0.83–2.32) 0.215
rs1514921 12q21.2 79,481,756 C/T 1.21 (0.89–1.64) 1.35 (0.72–2.53) 1.23 (0.94–1.62) 0.136
Table 1.  Results of the association analyses for cases and controls, the case-parent trios, and the combined 
meta-analysis.
SNP
Chromosome/
Region Position
Risk/other 
allele
Previous meta-analysis 
Draaken et al.5 RR (95% CI)
Replication RR 
(95% CI)
Present meta-analysis RR 
(95% CI) p values
rs6874700 5q11.2 50,701,750 A/T 2.17 (1.75–2.70) 1.75 (1.44–2.13) 1.93 (1.67–2.23) 9.2 × 10
−19
Table 2.  Results of our previous meta-analysis and the presently tested sample for the marker rs6874700.
www.nature.com/scientificreports/
4Scientific RepoRts | 7:42170 | DOI: 10.1038/srep42170
Isl1 is a transcription factor, containing LIM domains, which has been described as playing essential roles 
for the regulation of cell lineage commitment in organogenesis. It is essential for development of heart, kidney, 
neurons and limb15,16 however, the role of Isl1 in caudal embryonic region has been left unexplored. The cloaca 
is the essential embryonic structure to develop the external genitalia and the adjacent mesenchymes (termed as 
peri-cloacal mesenchyme, PCM)17. Cloacal epithelia and the surrounding mesenchyme interaction play a major 
role in caudal embryonic development. The mesenchyme adjacent to the cloaca receives cloacal derived signals 
and such mesenchyme includes the anterior part of the PCM (aPCM), which locates in the anterior (upper) part 
of the cloacal field17,18.
Our findings in CBE patients for the ISL1 locus are further supported by lineage analysis of Isl1-expressing 
cells in mouse embryos and mutant mice analysis of Isl1 cKO embryos. Isl1 marks the aPCM, which has been 
shown to contribute to the embryonic formation of the bladder, rectum, and the external genitalia19. As outlined 
above, many CBE patients present with additional anomalies of the human CAKUT spectrum including vesi-
coureteral reflux and obstruction of the ureteropelvic junction underlining that CBE affects all of the urinary 
tract system and not the bladder only. Thus, Isl1 cell lineages match with the organs reflecting various phenotypes 
of CBE. In the current study, we found that Isl1 is required for the caudal body formation including bladder and 
GT. The accurate lineage analyses of Isl1-expressing cells suggest that aPCM cells are specified to the bladder and 
external genitalia around at E7.5. Hence, the current study revealed the presence of the embryonic-time depend-
ent mesenchymal cell population as sensitive for the current set of genetic mutations. The epithelial-mesenchymal 
interaction between the epithelia and PCM is necessary to form the major parts of the caudal embryo. During 
such caudal embryonic development, several signaling pathways such as Bone morphogenetic protein (Bmp) and 
Sonic Hedgehog (Shh) are activated in the aPCM. On note, Defects of Bmp signals cause the body wall closure 
defects20,21. Another growth factor, Shh, is reported as expressed in the early staged cloacal epithelia affecting 
the adjacent PCM development17. It has been also shown that Shh signals relay to modulate mesenchymal Bmp 
signals22. Hence, the current analyses suggest that the signals including Shh, Bmp possibly affecting Isl1 lineage 
aPCM cells specified at early embryonic stage such as E7.5. Further analyses are required to understanding the 
molecular mechanisms for the bladder and body wall formation.
Using WISH analysis in early developmental stages of zfl (22–60 hpf), we were able to detect isl1 expression 
close to the proximal region of the developing pronephros for all tested time points. Later during development of 
zfl, the two nephrons fuse with the caudal end of the intestine, attaching at 96 hpf at the cloaca23. The pronephros 
filtrates the blood before delivering the waste to the cloaca for excretion, thus representing very premature struc-
tures of an urinary tract10. Therefore, even though isl1 could not be detected in the developing more distal cloaca 
or proctodeum regions in the zfl we analyzed, proximal expression of isl1 at regions of these early structures of 
mammalian urinary tract equivalents in zebrafish provides additional evidence for ISL1 as a regulator for urinary 
tract development across species.
We were not able to replicate any of the other 11 regions tested in our single-marker analysis. While we cannot 
exclude, that the inability to find further evidence for association for these 11 regions is based on a lack in statisti-
cal power of our present study, it is more likely, that these regions, respectively markers within these regions, had 
a higher effect in our previous meta-analysis (‘winner’s curse’) (208 CBE patients in total) than in our extended 
replication sample (268 CBE patients in total in our case-control study and 92 case-parent trios in our TDT). 
Figure 1. (A,B) Lineage analysis of Isl1-expressing cells at E10.5 and E15.5 by whole mount lacZ staining;  
(A) Contribution of Isl1-expressing cells in mouse embryos at E10.5 (white arrowhead); (B) Contribution of 
Isl1-expressing cells in mouse embryos at E15.5 (white arrow). (C–H) Lineage analysis of Isl1-expressing cells 
after administration of tamoxifen (TM) at E7.5–E9.5; (F–H) Mid-sagittal sections of bladder region at E12.5. 
The arrows and arrowheads indicate the bladder and genital tubercle, respectively. (I–L): Hypoplasia of GT and 
bladder in Isl1 cKO embryos.
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Alternatively, these regions might have been false positive signals in our previous meta-analysis, which were 
unrelated to CBE, or only show association with CBE patients of central European origin but not in CBE patient 
cohorts of different ethnicity. Finally, and most likely, our previous meta-analysis may have failed to identify the 
possible relevance of other markers and regions, that are actually involved in human CBE formation but were not 
considered for replication in our follow-up step since they might have obtained p values which were not consid-
ered worthy of note (e.g. p values > 10−5)5. It is therefore warranted, in order to identify additional markers and 
regions that might actually be involved in human CBE formation that we perform genome-wide genotyping of 
the present sample in a separate analysis. It is therefore warranted, in order to identify additional markers and 
regions that are actually involved in human CBE formation to perform genome-wide genotyping of the present 
sample in a separate analysis.
Within our replicated region of genome-wide significance and with an achieved p value of 1.14 × 10−10 
in our previous meta-analysis the marker rs2303751 in exon 4 of ISL1 reaches a score of 2b (scale 1a–6) in 
“RegulomeDB” (http://regulomedb.org) indicating that rs2303751 resides in a functional region. The marker 
rs2303751 alters 17 DNA binding motifs according to HaploReg v4.1, including alteration of the position-weight 
matrix for SMAD4, an essential downstream transcriptional regulator of the TGF beta signaling pathway24. In 
addition, the genomic region encompassing rs2303751 is occupied by EZH2 (enhancer of zeste 2), the major 
component of the genome regulating Polycomb Repressive Complex 2 (PRC2) and a therapeutic target in human 
bladder cancer25. With EZH2 being involved in human bladder cancer and with SMAD4 playing an essential role 
for initiating the smooth muscle cell differentiation program during ureter development, further analysis of the 
rs2303751 comprising region enclosing ISL1 is warranted24,25.
In addition, Kitchen et al., looking at methylation in low/intermediate grade non-muscle invasive bladder 
cancer, showed that the ISL1 genes’ promoter-associated island was more frequently methylated in recurrent and 
progressive high-grade tumors than their non-recurrent counterparts26. Since, Kolarova et al., were just recently 
able to provide certain lines of evidence, that imprinting might play a role in BEEC formation, further studies 
regarding differences in methylation of the ISL1 region in CBE patients compared to matched controls are also 
warranted27.
Conclusion
Our present association study in CBE patients together with functional studies in mouse embryos and zebrafish 
larvae suggest ISL1 as a regulator of urinary tract development.
Figure 2. WISH against isl1 (antisense 3′-untranslated region-probe; upper row), slc20a1a (middle 
row) and both probes combined (lower row) on wild-type zfl at 48 hpf. 48 hpf long-pec stage zfl in lateral 
(left column) and dorsal view (middle column; same fish; scale bar = 500 μm) in the top row are showing isl1 
expression amongst other previous described regions also at most anterior regions of the proximal convoluted 
tubular (PCT; arrows). 25 μm transversal slices sections of the same fish are shown in the right column (scale 
bar = 150 μm). The orientation of sections is shown with red dashed lines in the corresponding whole mount 
images. The zfl show a clear isl1 staining in what has previously been described as the developing pancreatic 
region, and which might well be overlapping with an anterior region of the slc20a1a labeled PCT (black arrow 
heads). The overlap of isl1 and slc20a1a expression at this region is further supported by the fact that no 
additional stained area could be found there, when we used both in situ probes simultaneously for staining. Isl1 
expression could not be detected in the developing cloaca or proctodeum region (not shown).
www.nature.com/scientificreports/
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Materials and Methods
Ethics statement and subjects. This study was approved by each participating center’s institutional ethics 
committee. All methods were carried out in accordance with relevant guidelines and regulations. All experimen-
tal protocols were approved by the institutional committee of the University of Bonn. Furthermore the study 
was conducted according to Declaration of Helsinki principles. Written informed consent was obtained from all 
patients, parents/guardians and the normal controls. Demographic information was collected from both, patients 
and controls, through a structured questionnaire. Experienced physicians trained in the diagnosis of the BEEC 
personally recruited all BEEC patients included in this study.
The study sample comprised 274 Australian (n = 36), British (n = 40), German (n = 7), Italian (n = 40), 
Spanish (n = 35), and Swedish (n = 116) CBE patients and 1,365 ethnically matched controls, and 110 case-parent 
trios from North America of European background. Peripheral venous blood samples, saliva samples or buccal 
swab samples were obtained from patients and controls for DNA extraction. More details about the recruitment 
process for patients and population based respectively phenotype unrelated controls can be found elsewhere and 
in the Supplementary ‘Materials, Methods’5,6,27–30.
Genotyping. For SNP-marker genotyping, we used the Sequenom MALDI-TOF mass-spectrometer 
(MassArray system), TaqMan® SNP genotyping assays (Life Technologies Europe BV, Netherlands) and conven-
tional Sanger sequencing. Sequenom data were analyzed using the Spectrodesigner Software package (Sequenom, 
San Diego, CA) and allele peaks were analyzed with the Sequenom Typer Analysis software. TaqMan generated 
data were analyzed using the ABI 7900HT instrument and the SDS software (v2.4, Applied Biosystems). Sanger 
sequencing generated data were analyzed using CodonCode Aligner software package (CodonCode Corporation, 
MA, USA).
Statistical analysis. Statistical analysis was performed using SAS software (version 9.1). The standard 
chi-square test was used to test for deviations from Hardy-Weinberg equilibrium. The two-sided Armitage’s trend 
test was used to compare genotype distributions between cases and controls separately in each case-control sub-
sample. In order to test for association of the risk alleles with CBE in trios from North America, we applied the 
transmission/disequilibrium test (TDT)31. Fixed effects meta-analysis was used to combine samples32.
Embryo collections for lineage analysis of Isl1-expressing cells and analysis of knockout 
mouse embryos. All experimental procedures and protocols were approved by the Committees on Animal 
Research at Wakayama Medical University and the experiments were carried out in accordance with the approved 
guidelines. Each mouse strain used in this study Isl1flox/flox conditional mutant allele, Hoxa3-IRESCre, 
Isl1-mER-Cre-mERm and R26R-LacZ indicator strain was described previously7,8,33–35. The tamoxifen 
(TM)-inducible Cre recombinase system removes the floxed sequence from the target genome31. TM (Sigma, 
St Louis, MO, USA) was dissolved in sesame oil at 10 mg/ml and injected into pregrant female by oral admin-
istration at a dose of 0.05 mg/g of body weight. The mice for Isl1 positive-lineage analyses used in this study 
were Isl1-mER-Cre-mER and R26R-LacZ indicator strains. These mice strains were generated as described pre-
viously7,34. TM was administrated from embryonic days (E) 7.5 to E9.5 and the embryos were harvested at E10.5, 
E12.5 and E15.5, respectively. X-gal staining for the detection of Isl1-expressing cells was performed as previously 
described33,36. Briefly, freshly dissected embryos were fixed 1 hour in a solution composed of 1% formaldehyde 
and 0.2% glutaraldehyde at 4 °C. The embryos were washed with PBS and color development was performed with 
the developing solution. For histological analysis of the Isl1-expressing cells, the X-gal stained specimens were 
refixed overnight in 4% paraformaldehyde (PFA)/PBS, dehydrated in methanol and embedded in paraffin. 10 μm 
serial sections were prepared and stained by Eosin.
For analysis of Hoxa3-IRESCre; Isl1 mutant embryos (hereafter described as Isl1 cKO), we mated 
Hoxa3-IRESCre; Isl1Flox/+ with Isl1Flox/Flox, and subsequently harvested at E13.5. Embryonic specimens were 
fixed overnight in 4% paraformaldehyde (PFA)/PBS, dehydrated in methanol, and embedded in paraffin. Serial 
sections (6-μm thick) were prepared for hematoxylin/eosin (H&E) staining.
Whole mount in situ hybridization (WISH) of zebrafish larvae (zfl). All experimental procedures 
and protocols were carried out in accordance with the approved national guidelines. Zfl for the presented exper-
iments were maintained and staged as described elsewhere14,37. Mixed Tübingen long fin (TL) and Ekkwill (EK) 
strain wild-type (wt) embryos were used for all experiments. All embryos were gained by natural fish spawning 
set up in the mornings and raised at 28 °C in Danieau (30%) medium, following local and international animal 
procedure standards. To analyse isl1-expression in zfl mRNA WISH was performed in embryos of different ages 
(22 hpf, 48 hpf and 60 hpf). We mainly followed a WISH standard protocol using an anti-Dig Ab-dilution of 
1:10:00037. The RNA in-situ probe was designed for binding at the 5′ untranslated (UTR) region of zf isl1 using the 
following forward primer (CATCATctcgagAGAGTGACATCGACCAGCCTGCTTTCC) and the reverse primer 
(CATCATggatccGAAATTCCCACACAGCTTGTGGC) on cDNA of 1 dpf whole zfl. The resulting amplified PCR 
product of the probe was then cloned into SK(-)pBluescript® using BamHI and XhoI sites and sequenced. We 
used the DIG RNA Labeling Kit (SP6/T7) (Roche; product number: 11175025910) to transcribe an antisense 
(T3) and a sense probe (T7) as negative control (not shown) from the above plasmid. Final imaging of the WISH 
stained larvae fish was performed using an Eclipse upright microscope (Nikon) equipped with a 10x and 40x 
objectives (NA = 0.25 and 0.65 respectively) and a DS-Vi1 digital colour camera run by NIS-Element software 
(Nikon).
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